Quantum‐Chemical Evaluation of the Interaction Between the Mycobacterium tuberculosis Dihydrofolate Reductase Enzyme With Classical and Potential Inhibitors
Abstract
Tuberculosis (TB) remains a major global threat, demanding new therapeutic strategies. Dihydrofolate reductase (DHFR), essential for cell survival and a known drug target, has emerged as a promising enzyme for anti‐TB drug development. Using crystallographic structures of Mycobacterium tuberculosis DHFR (MtDHFR) complexed with classical and potential inhibitors, a quantum‐chemical analysis was performed through the molecular fractionation with conjugate caps (MFCC) scheme within the density functional theory (DFT) framework to quantify individual amino acid contributions to ligand‐protein interactions. Energetically significant interactions were observed within a 6.0 Å pocket, when convergence of the total interaction energy (TIE) was found. The key residues I5, W6, D19, I20, R23, D27, Q28, H30, F31, R32, L50, K53, L57, R60, I94, and E111 were identified, along with the energetically relevant regions of the ligands and the major secondary structures of the protein. These results may guide the design of new anti‐TB drugs.
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.